Piper Sandler analyst Kelsey Goodwin downgraded Day One Biopharmaceuticals (DAWN) to Neutral from Overweight with a price target of $21.50, down from $25, after the company agreed to be acquired by Servier for $21.50 per share in cash.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DAWN:
- Day One Biopharmaceuticals downgraded to Neutral from Outperform at Wedbush
- Day One Biopharmaceuticals downgraded to Hold from Buy at JonesResearch
- Servier to Acquire Day One Biopharmaceuticals in Merger
- Day One Biopharmaceuticals trading resumes
- Servier to acquire Day One for $21.50 per share in cash